Your Location: Set Your Location
Your location:
See services nearest you.
Menu
Search
Essentia Health Menu
Home > Education & Research > Research to Improve Health Care > Participating in Research > Clinical Trials > Clinical Trials Details
Back to Results
This randomized phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient DNA mismatch repair colorectal cancer that has spread to other places in the body. Drugs used in chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab and atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.
https://www.clinicaltrials.gov/ct2/show/NCT02997228
Contact Phone: 218-786-3308 | 1-844-681-7944
Email: cancertrials@essentiahealth.org
Locations: Essentia Health Cancer Centers
Disclosures:
None
For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.